Xenon (XENE) CMO Christopher Kenney Sells Shares

What Happened
Christopher John Kenney, Chief Medical Officer of Xenon Pharmaceuticals (XENE), sold a total of 7,068 shares in open-market transactions on August 28, 2026. The filing reports two grouped sales: 6,368 shares at a weighted-average price of $60.17 for proceeds of $383,145, and 700 shares at a weighted-average price of $60.98 for proceeds of $42,684 — approximately $425,829 in total. These are sales (not purchases), which are commonly routine dispositions by insiders.

Key Details

• Transaction date: August 28, 2026 (filed with the SEC on August 31, 2026); filing appears timely.
• Prices reported:
  • 6,368 shares at weighted avg $60.17 (individual trade prices ranged $59.79–$60.68).
  • 700 shares at weighted avg $60.98 (individual trade prices ranged $60.81–$61.12).
• Total shares sold: 7,068; total proceeds reported ≈ $425,829.
• Shares owned after the reported transactions: the filing notes an upward adjustment of one share from the reporting person’s prior Form 4 (filed Mar 13, 2026); the summary provided here does not include the final total beneficial ownership count.
• Notable footnotes:
  • Sales were effected under a Rule 10b5‑1 trading plan adopted May 29, 2026 (prearranged plan).
  • The filing reports aggregated amounts and weighted-average prices and provides price ranges for the individual trades; the filer offers to supply per-price breakdowns on request.

Context

• The use of a 10b5‑1 plan means the trades were preplanned and generally limit inference about contemporaneous insider knowledge; it’s a common mechanism for insiders to sell shares on a set schedule.
• Sales are informative for tracking insider liquidity but are less indicative of positive company outlook than purchases; stay focused on company fundamentals and follow-up filings for more signals.